Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally.
Excellent balance sheet with proven track record.
Share Price & News
How has Virbac's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VIRP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VIRP matched the French Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: VIRP exceeded the French Market which returned -3.8% over the past year.
Price Volatility Vs. Market
How volatile is Virbac's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StIs Virbac SA's (EPA:VIRP) CEO Overpaid Relative To Its Peers?
2 weeks ago | Simply Wall StAre Virbac SA's (EPA:VIRP) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
1 month ago | Simply Wall StI Ran A Stock Scan For Earnings Growth And Virbac (EPA:VIRP) Passed With Ease
Is Virbac undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VIRP (€195) is trading below our estimate of fair value (€243.19)
Significantly Below Fair Value: VIRP is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: VIRP is poor value based on its PE Ratio (31.9x) compared to the Pharmaceuticals industry average (23.9x).
PE vs Market: VIRP is poor value based on its PE Ratio (31.9x) compared to the French market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: VIRP is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: VIRP is overvalued based on its PB Ratio (3.2x) compared to the FR Pharmaceuticals industry average (2.5x).
How is Virbac forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIRP's forecast earnings growth (14.6% per year) is above the savings rate (0.6%).
Earnings vs Market: VIRP's earnings (14.6% per year) are forecast to grow faster than the French market (13.6% per year).
High Growth Earnings: VIRP's earnings are forecast to grow, but not significantly.
Revenue vs Market: VIRP's revenue (2.8% per year) is forecast to grow slower than the French market (3.9% per year).
High Growth Revenue: VIRP's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIRP's Return on Equity is forecast to be low in 3 years time (9.4%).
How has Virbac performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIRP has high quality earnings.
Growing Profit Margin: VIRP's current net profit margins (5.5%) are higher than last year (2.3%).
Past Earnings Growth Analysis
Earnings Trend: VIRP's earnings have declined by -7.8% per year over the past 5 years.
Accelerating Growth: VIRP's earnings growth over the past year (156.5%) exceeds its 5-year average (-7.8% per year).
Earnings vs Industry: VIRP earnings growth over the past year (156.5%) exceeded the Pharmaceuticals industry 5.5%.
Return on Equity
High ROE: VIRP's Return on Equity (9.9%) is considered low.
How is Virbac's financial position?
Financial Position Analysis
Short Term Liabilities: VIRP's short term assets (€450.9M) exceed its short term liabilities (€372.5M).
Long Term Liabilities: VIRP's short term assets (€450.9M) exceed its long term liabilities (€398.9M).
Debt to Equity History and Analysis
Debt Level: VIRP's debt to equity ratio (77.3%) is considered high.
Reducing Debt: VIRP's debt to equity ratio has reduced from 117.7% to 77.3% over the past 5 years.
Debt Coverage: VIRP's debt is well covered by operating cash flow (30.8%).
Interest Coverage: VIRP's interest payments on its debt are well covered by EBIT (6.7x coverage).
What is Virbac's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIRP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIRP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIRP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIRP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: VIRP is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIRP's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sébastien Huron (48yo)
Mr. Sébastien Huron has been Chairman of Executive Board at Virbac SA since December 20, 2017. He served as the Head of Global Business Operations at Virbac SA since 2014 and has been its Member of Executi ...
CEO Compensation Analysis
Compensation vs Market: Sébastien's total compensation ($USD629.09K) is below average for companies of similar size in the French market ($USD1.16M).
Compensation vs Earnings: Sébastien's compensation has been consistent with company performance over the past year.
|Chairman of the Executive Board||2.5yrs||€555.36k||0.011% €189.0k|
|CFO & Member of Executive Board||4yrs||€298.77k||no data|
|Executive VP of Corporate Development||23.5yrs||€1.15m||0.066% €1.1m|
|Head of Corporate Communications||no data||no data||no data|
|Head of Corporate Human Resources||no data||no data||no data|
|Head of Global Industrial Operations & Corporate Quality Assurance||no data||no data||no data|
|Director of Financial Projects||no data||no data||no data|
Experienced Management: VIRP's management team is considered experienced (4 years average tenure).
|Independent Member of the Supervisory Board||9.42yrs||€21.00k||0.00012% €2.0k|
|Vice Chairman of Supervisory Board||no data||€21.00k||0.0013% €21.5k|
|Chairwoman of Supervisory Board||14.17yrs||€116.00k||49.85% €819.2m|
|Non-Voting Advisor||no data||€21.00k||no data|
|Independent Member of the Supervisory Board||16.42yrs||€24.00k||0.0052% €86.1k|
|Independent Member of Supervisory Board||1yr||no data||0.00012% €2.0k|
|Member of Supervisory Board||2.75yrs||€21.00k||0.00012% €2.0k|
|Employee Representative of Supervisory Board||2.42yrs||no data||no data|
Experienced Board: VIRP's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Virbac SA's company bio, employee growth, exchange listings and data sources
- Name: Virbac SA
- Ticker: VIRP
- Exchange: ENXTPA
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.643b
- Shares outstanding: 8.43m
- Website: https://corporate.virbac.com
Number of Employees
- Virbac SA
- 13e rue LID - BP 27
- Provence-Alpes-Côte d'Azur
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VIRP||ENXTPA (Euronext Paris)||Yes||Share Capital||FR||EUR||Jan 1992|
|0NM7||LSE (London Stock Exchange)||Yes||Share Capital||GB||EUR||Jan 1992|
|VRBC.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Jan 1992|
|V16||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jan 1992|
|VIRPP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||EUR||Jan 1992|
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine, a contraceptive for dogs; Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; Browse Plus, a food supplement for food producing animals; and C.E.T. Veggiedent Flex, C.E.T. Veggiedent Fr3sh, and C.E.T. Veggiedent Zen to treat bad breath in dogs. It also provides Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Easotic, an auricular treatment for otitis; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; Eradia to treat clostridium infections and giardiasis; Evicto, a selamectin-based endectocide treatment; Fosfosal, a trace mineral injectable supplementation; and Grofactor, a growth promoter. In addition, the company offers Hyaloral, a food supplement in tablet or gel form; Kriptazen, a halofuginone-based antiprotozoal solution; Luminal, phenobarbital-based tablet; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement; Nutri-plus gel, a food supplement in oral gel form; Prevendog, deltamethrin-based parasiticides collar; Pronefra, a food supplement in case of chronic kidney disease; and Sentinel Flavor Tabs et Sentinel Spectrum, a polyvalent parasiticide tablet. Further, it provides Shotapen to treat bacterial infections; Suigen PCV2, a vaccine against porcine circovirus; Suramox, a coated amoxicillin-based antibiotic; Suprelorin, a deslorelin-based implant; Syvazul, a bluetongue vaccine; Vetemex, an antiemetic solution; Virbagest, an altrenogest-based progestin; Virbamec Platinum, an injectable solution; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 21:16|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.